Quest PharmaTech, AD Biotech form joint cancer venture

Wednesday, July 24, 2013 02:15 PM

Quest PharmaTech, a pharmaceutical company developing and commercializing cancer treatment products, has entered into a relationship with Korean-based AD Biotech to share research and technology development resources to co-develop technologies of both companies.

AD Biotech has provided $2 million of clinical development funding to Quest and will provide up to $10 million for common shares and future revenue sharing. The deal enables Quest to fund its clinical development programs (including those for its newly acquired IgE technology) and gives Quest access to AD Biotech's antibody, protein transduction domain and manufacturing technologies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs